UCB Pharma, Slough, UK.
Sci Rep. 2017 Aug 30;7(1):9963. doi: 10.1038/s41598-017-10298-x.
Fibrosis is a common driver of end-stage organ failure in most organs. It is characterised by excessive accumulation of extracellular matrix (ECM) proteins. Therapeutic options are limited and novel treatments are urgently required, however current cell-based high-throughput screening (HTS) models to identify molecules affecting ECM accumulation are limited in their relevance or throughput. We report a novel sensitive approach which combines in situ fluorescent staining of accumulated decellularised ECM proteins with automated high-content microscopy. Using this method to measure ECM accumulation in a kidney cell model, we demonstrated good agreement with established radiolabelled amino acid incorporation assays: TGFβ1 delivered a potent pro-fibrotic stimulus, which was reduced by TGFβ antibody or the anti-fibrotic nintedanib. Importantly, our method also provides information about matrix organisation: the extent of ECM accumulation was unaffected by the BMP antagonist Gremlin-1 but a pronounced effect on matrix fibrillar organisation was revealed. This rapid, straightforward endpoint provides quantitative data on ECM accumulation and offers a convenient cross-species readout that does not require antibodies. Our method facilitates discovery of novel pro- and anti-fibrotic agents in 384-well plate format and may be widely applied to in vitro cell-based models in which matrix protein deposition reflects the underlying biology or pathology.
纤维化是大多数器官终末期器官衰竭的常见驱动因素。它的特征是细胞外基质 (ECM) 蛋白的过度积累。治疗选择有限,迫切需要新的治疗方法,然而,目前用于识别影响 ECM 积累的分子的基于细胞的高通量筛选 (HTS) 模型在相关性或通量方面存在局限性。我们报告了一种新颖的敏感方法,该方法将累积去细胞 ECM 蛋白的原位荧光染色与自动化高内涵显微镜结合使用。使用这种方法测量肾细胞模型中的 ECM 积累,我们证明与已建立的放射性标记氨基酸掺入测定法具有良好的一致性:TGFβ1 传递了强烈的促纤维化刺激,该刺激被 TGFβ 抗体或抗纤维化尼达尼布减弱。重要的是,我们的方法还提供了有关基质组织的信息:ECM 积累的程度不受 BMP 拮抗剂 Gremlin-1 的影响,但明显影响了基质纤维状组织。这种快速、直接的终点提供了关于 ECM 积累的定量数据,并提供了一种方便的跨物种读出,不需要抗体。我们的方法有助于在 384 孔板格式中发现新型促纤维化和抗纤维化剂,并且可以广泛应用于基于细胞的体外模型,其中基质蛋白沉积反映了潜在的生物学或病理学。